- New leadership to harness the full strength of Novartis organizations in Canada
DORVAL, QC, May 8, 2019 /CNW/ - Christian Macher, General Manager of Novartis Oncology Canada, has been named country President of Novartis Canada, effective May 1, 2019. In addition to his role as General Manager of Novartis Oncology, Christian now takes on overall leadership of all company activities in Canada and will work in collaboration with senior leadership of the Novartis Pharmaceuticals business unit and Sandoz.
Novartis in Canada includes the Innovative Medicines division with its Pharmaceuticals and Oncology businesses, headquartered in Dorval, Quebec, as well as Sandoz Canada, providing generic drugs, biosimilars and specialty treatments, based in Boucherville, Quebec.
Christian Macher takes on this role with more than 20 years of pharmaceutical industry experience. Having worked in key positions globally, he is an accomplished marketing leader with a proven track record of effective leadership and driving business growth. In his most recent role as a global marketing head at AstraZeneca in the UK, Mr. Macher led a key oncology portfolio and the breast cancer strategy. Prior to that he headed the company's business in Taiwan in the role of Country President. While in Taiwan Mr. Macher played an active role in policy and government relations serving as co-chair of the pharmaceutical industry association (IRPMA Taiwan) and the Pharmaceutical Working Group of the European Chamber of Commerce, as well as serving on the British Chamber of Commerce Taiwan.
"It was very exciting to have been offered the role of Oncology General Manager and being recently appointed country President is an even greater honour," said Christian Macher. "Having worked alongside the team over the past few months, I can say without hesitation that the talented individuals at Novartis are genuine and committed to reimagining medicine to help improve the lives of Canadians. I look forward to the how we will continue to support patients and innovate across the different portfolios and Novartis divisions."
Mr. Macher holds a bachelor's degree in chemistry from Technical University Munich, Germany, as well as a master's degree in chemistry and a PhD in organic chemistry from ETH Zurich, Switzerland. He is fluent in German and English and also speaks French and Spanish.
About Novartis in Canada
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2018, the company invested $52 million in research and development in Canada. Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. employs approximately 1,000 people in Canada and is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. For further information, please consult www.novartis.ca.
About Sandoz in Canada
Sandoz Canada is part of Sandoz International GmbH, a global leader in generic pharmaceuticals and biosimilars and a subsidiary of the Swiss multinational Novartis AG. A leader in its field, Sandoz Canada markets and distributes a broad line of generic, biosimilar, consumer and specialty products. For more information, visit www.sandoz.ca. Follow us on LinkedIn: https://www.linkedin.com/company/sandoz-canada//
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
SOURCE Novartis Pharmaceuticals Canada Inc.
For further information: Novartis Media Relations, Daphne Weatherby, Novartis Corporate Communications, +1 514 633 7873, E-mail: email@example.com